{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-004858","form_type":"8-K","ticker":"BEAM","cik":"0001745999","company_name":"Beam Therapeutics Inc.","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.390383+00:00","generated_at":"2026-06-18T22:26:40.548277+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Beam Therapeutics reports Q4 2022 net loss of $38.3M; cash at $1.1B, runway into 2025","bullets":["Net loss Q4 2022: $38.3M ($0.54/share) vs $64.7M ($0.95/share) in Q4 2021; full year net loss $289.1M ($4.13/share).","Cash, cash equivalents and marketable securities $1.1B as of Dec 31, 2022, up from $965.6M at Dec 31, 2021.","R&D expenses $86.3M in Q4 2022, down from $96.8M in Q4 2021; G&A expenses $22.7M vs $17.8M.","Pipeline milestones: BEAM-101 sentinel cohort enrollment to finish 2023, BEAM-201 first patient dosing by mid-2023, BEAM-301 and BEAM-302 regulatory filings in late 2023/early 2024.","North Carolina manufacturing facility expected to commence cGMP operations in late 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-004858","json":"https://secwatch.observer/filing/0000950170-23-004858.json","markdown":"https://secwatch.observer/filing/0000950170-23-004858.md","text":"https://secwatch.observer/filing/0000950170-23-004858.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1745999/000095017023004858/0000950170-23-004858-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1745999/000095017023004858/beam-20230228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T22:26:40.548277+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"37993130c95d567474ade21ed1287a5c03639df3","claim":"Beam Therapeutics Inc. reported the fourth quarter of 2022 results: net income Net loss attributable to common stockholders was $38.3 million, or $0.54 per share, for the fourth quarter of 2022, EPS $0.54 per share. Guidance reaffirmed.","evidence_excerpt":"issued a press release announcing the Company’s financial results for the quarter ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1745999/000095017023004858/0000950170-23-004858-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter of 2022"},{"label":"Net income","value":"Net loss attributable to common stockholders was $38.3 million, or $0.54 per share, for the fourth quarter of 2022"},{"label":"EPS","value":"$0.54 per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}